Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
10 Pharmacists who are aware of cases of exenatide-associated acute pancreatitis or other serious adverse drug reactions are encouraged to report their findings to MedWatch, the FDAs adverse drug reporting program (www.fda.gov/Safety/MedWatch/ Anti-exenatide Antibodies: In phase III clinical trials, 41% to 49% of patients receiving exenatide developed anti-exenatide antibodies
Extended Data Figure 3 The GLP-1R StaR B-factors and electron density
The role of EPACs in melanomagenesis in vivo and the molecular mechanisms through which EPACs selectively promote the growth of primary melanoma cells remain to be understood
Resolving the topological enigma in Ca(2+) signaling by cyclic ADP-ribose and NAADP
To view or add a comment, sign in A timely review in JPAD highlights the potential of tau as both a promising therapeutic target and as a valuable biological marker
LiTZhaoMRazaAGuoJHeTZouTet al
US$ 26.53
US$ 22.68
US$ 27.05
US$ 29.51
